{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T08:42:22Z","timestamp":1795250542784,"version":"4.10.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10549-022-06692-3","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T06:08:51Z","timestamp":1659679731000},"page":"453-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine"],"prefix":"10.1007","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2222-1683","authenticated-orcid":false,"given":"Anastasiia","family":"Samusieva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1875-3185","authenticated-orcid":false,"given":"Svitlana","family":"Serga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9758-7316","authenticated-orcid":false,"given":"Sergiy","family":"Klymenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6759-9650","authenticated-orcid":false,"given":"Lyudmila","family":"Rybchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-2853","authenticated-orcid":false,"given":"Bohdana","family":"Klimuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-9970","authenticated-orcid":false,"given":"Liubov","family":"Zakhartseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-7166","authenticated-orcid":false,"given":"Natalia","family":"Gorovenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1900-5816","authenticated-orcid":false,"given":"Olga","family":"Lobanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4767-7364","authenticated-orcid":false,"given":"Zoia","family":"Rossokha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9999-7389","authenticated-orcid":false,"given":"Liliia","family":"Fishchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5261-6980","authenticated-orcid":false,"given":"Nataliia","family":"Levkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8005-7220","authenticated-orcid":false,"given":"Nataliia","family":"Medvedieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8838-8219","authenticated-orcid":false,"given":"Olena","family":"Popova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9799-3752","authenticated-orcid":false,"given":"Valeriy","family":"Cheshuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-9386","authenticated-orcid":false,"given":"Mariia","family":"Inomistova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-2540","authenticated-orcid":false,"given":"Natalia","family":"Khranovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-6397","authenticated-orcid":false,"given":"Oksana","family":"Skachkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3551-2148","authenticated-orcid":false,"given":"Yurii","family":"Michailovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2466-3277","authenticated-orcid":false,"given":"Olga","family":"Ponomarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6485-1408","authenticated-orcid":false,"given":"Iryna","family":"Kozeretska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"6692_CR1","unstructured":"CANCER IN UKRAINE 2019\u20132020 - Bulletin of the National Cancer Registry of Ukraine Vol.22. Accessed 9 Nov 2021 http:\/\/www.ncru.inf.ua\/publications\/BULL_22\/index_e.htm."},{"key":"6692_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jcp.10257","volume":"196","author":"EM Rosen","year":"2003","unstructured":"Rosen EM, Fan S, Pestell RG, Goldberg ID (2003) BRCA1 gene in breast cancer. J Cell Physiol 196:19\u201341. https:\/\/doi.org\/10.1002\/jcp.10257","journal-title":"J Cell Physiol"},{"key":"6692_CR3","doi-asserted-by":"publisher","first-page":"14537","DOI":"10.1074\/jbc.C000881200","volume":"276","author":"R Hashizume","year":"2001","unstructured":"Hashizume R, Fukuda M, Maeda I et al (2001) The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276:14537\u201314540. https:\/\/doi.org\/10.1074\/jbc.C000881200","journal-title":"J Biol Chem"},{"key":"6692_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1158\/2159-8290.CD-12-0221","volume":"2","author":"DP Silver","year":"2012","unstructured":"Silver DP, Livingston DM (2012) Mechanisms of BRCA1 tumor suppression. Cancer Discov 2:679\u2013684. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0221","journal-title":"Cancer Discov"},{"key":"6692_CR5","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.7150\/jca.30410","volume":"10","author":"I Gorodetska","year":"2019","unstructured":"Gorodetska I, Kozeretska I, Dubrovska A (2019) BRCA genes: the role in genome stability, cancer stemness and therapy resistance. J Cancer 10:2109\u20132127. https:\/\/doi.org\/10.7150\/jca.30410","journal-title":"J Cancer"},{"key":"6692_CR6","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.1073\/pnas.0811159106","volume":"106","author":"SMH Sy","year":"2009","unstructured":"Sy SMH, Huen MSY, Chen J (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A 106:7155\u20137160. https:\/\/doi.org\/10.1073\/pnas.0811159106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6692_CR7","doi-asserted-by":"publisher","DOI":"10.5936\/csbj.201204005","volume":"1","author":"SL Clark","year":"2012","unstructured":"Clark SL, Rodriguez AM, Snyder RR et al (2012) Structure-function of the tumor suppressor BRCA1. Comput Struct Biotechnol J 1:e201204005. https:\/\/doi.org\/10.5936\/csbj.201204005","journal-title":"Comput Struct Biotechnol J"},{"key":"6692_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ejhg.2012.124","volume":"21","author":"Y Laitman","year":"2013","unstructured":"Laitman Y, Feng B-J, Zamir IM et al (2013) Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet 21:212\u2013216. https:\/\/doi.org\/10.1038\/ejhg.2012.124","journal-title":"Eur J Hum Genet"},{"key":"6692_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/ng1295-428","volume":"11","author":"SA Gayther","year":"1995","unstructured":"Gayther SA, Warren W, Mazoyer S et al (1995) Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11:428\u2013433. https:\/\/doi.org\/10.1038\/ng1295-428","journal-title":"Nat Genet"},{"key":"6692_CR10","unstructured":"Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine - PubMed. Accessed 8 Nov 2021 https:\/\/pubmed.ncbi.nlm.nih.gov\/28285342\/."},{"key":"6692_CR11","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.ejca.2006.01.050","volume":"42","author":"AP Sokolenko","year":"2006","unstructured":"Sokolenko AP, Mitiushkina NV, Buslov KG et al (2006) High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur J Cancer 42:1380\u20131384. https:\/\/doi.org\/10.1016\/j.ejca.2006.01.050","journal-title":"Eur J Cancer"},{"key":"6692_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10689-014-9721-8","volume":"13","author":"A Savanevich","year":"2014","unstructured":"Savanevich A, Oszurek O, Lubi\u0144ski J et al (2014) BRCA1 founder mutations compared to ovarian cancer in Belarus. Fam Cancer 13:445\u2013447. https:\/\/doi.org\/10.1007\/s10689-014-9721-8","journal-title":"Fam Cancer"},{"key":"6692_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.cca.2007.12.024","volume":"390","author":"C Kroupis","year":"2008","unstructured":"Kroupis C, Christopoulos K, Devetzoglou M et al (2008) Asymmetric real-time PCR detection of BRCA1 5382insC mutation by melting curve analysis in the lightcycler. Clin Chim Acta 390:141\u2013144. https:\/\/doi.org\/10.1016\/j.cca.2007.12.024","journal-title":"Clin Chim Acta"},{"key":"6692_CR14","doi-asserted-by":"publisher","unstructured":"The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine | Hereditary Cancer in Clinical Practice | Full Text. Accessed 8 Nov 2021 https:\/\/hccpjournal.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s13053-015-0040-3.","DOI":"10.1186\/s13053-015-0040-3"},{"key":"6692_CR15","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1158\/1055-9965.EPI-08-0544","volume":"17","author":"L Vona-Davis","year":"2008","unstructured":"Vona-Davis L, Rose DP, Hazard H et al (2008) Triple-negative breast cancer and obesity in a rural appalachian population. Cancer Epidemiol Biomarkers Prev 17:3319\u20133324. https:\/\/doi.org\/10.1158\/1055-9965.EPI-08-0544","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"6692_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747\u2013752. https:\/\/doi.org\/10.1038\/35021093","journal-title":"Nature"},{"key":"6692_CR17","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492\u20132502. https:\/\/doi.org\/10.1001\/jama.295.21.2492","journal-title":"JAMA"},{"key":"6692_CR18","unstructured":"Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk | NEJM. Accessed 8 Nov 2021 https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmsr1501341."},{"key":"6692_CR19","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/bjc.2012.31","volume":"106","author":"L Robertson","year":"2012","unstructured":"Robertson L, Hanson H, Seal S et al (2012) BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 106:1234\u20131238. https:\/\/doi.org\/10.1038\/bjc.2012.31","journal-title":"Br J Cancer"},{"key":"6692_CR20","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","volume":"26","author":"DP Atchley","year":"2008","unstructured":"Atchley DP, Albarracin CT, Lopez A et al (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282\u20134288. https:\/\/doi.org\/10.1200\/JCO.2008.16.6231","journal-title":"J Clin Oncol"},{"key":"6692_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120189","volume":"10","author":"AJ van den Broek","year":"2015","unstructured":"van den Broek AJ, Schmidt MK, van \u2018t Veer LJ, et al (2015) Worse Breast cancer prognosis of BRCA1\/BRCA2 mutation Carriers: what\u2019s the evidence? a systematic review with meta-analysis. PLoS ONE 10:e0120189. https:\/\/doi.org\/10.1371\/journal.pone.0120189","journal-title":"PLoS ONE"},{"key":"6692_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3892\/ol.2013.1684","volume":"7","author":"J Maksimenko","year":"2014","unstructured":"Maksimenko J, Irmejs A, Nakazawa-Miklasevica M et al (2014) Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer. Oncol Lett 7:278\u2013284. https:\/\/doi.org\/10.3892\/ol.2013.1684","journal-title":"Oncol Lett"},{"key":"6692_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","volume":"19","author":"ER Copson","year":"2018","unstructured":"Copson ER, Maishman TC, Tapper WJ et al (2018) Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 19:169\u2013180. https:\/\/doi.org\/10.1016\/S1470-2045(17)30891-4","journal-title":"Lancet Oncol"},{"key":"6692_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/gcc.20833","volume":"50","author":"SA Joosse","year":"2011","unstructured":"Joosse SA, Brandwijk KIM, Mulder L et al (2011) Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosomes Cancer 50:71\u201381. https:\/\/doi.org\/10.1002\/gcc.20833","journal-title":"Genes Chromosomes Cancer"},{"key":"6692_CR25","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/gtc.12100","volume":"18","author":"Y Watanabe","year":"2013","unstructured":"Watanabe Y, Maeda I, Oikawa R et al (2013) Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy. Genes Cells 18:1120\u20131130. https:\/\/doi.org\/10.1111\/gtc.12100","journal-title":"Genes Cells"},{"key":"6692_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/CLEP.S206949","volume":"11","author":"N Armstrong","year":"2019","unstructured":"Armstrong N, Ryder S, Forbes C et al (2019) A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol 11:543\u2013561. https:\/\/doi.org\/10.2147\/CLEP.S206949","journal-title":"Clin Epidemiol"},{"key":"6692_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","volume":"33","author":"FJ Couch","year":"2015","unstructured":"Couch FJ, Hart SN, Sharma P et al (2015) Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 33:304\u2013311. https:\/\/doi.org\/10.1200\/JCO.2014.57.1414","journal-title":"J Clin Oncol"},{"key":"6692_CR28","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","volume":"3","author":"E Hahnen","year":"2017","unstructured":"Hahnen E, Lederer B, Hauke J et al (2017) Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the geparsixto randomized clinical trial. JAMA Oncol 3:1378\u20131385. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1007","journal-title":"JAMA Oncol"},{"key":"6692_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12967-019-1873-8","volume":"17","author":"W Mahfoudh","year":"2019","unstructured":"Mahfoudh W, Bettaieb I, Ghedira R et al (2019) Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia. J Transl Med 17:123. https:\/\/doi.org\/10.1186\/s12967-019-1873-8","journal-title":"J Transl Med"},{"key":"6692_CR30","doi-asserted-by":"publisher","first-page":"8545643","DOI":"10.1155\/2020\/8545643","volume":"2020","author":"K Pogoda","year":"2020","unstructured":"Pogoda K, Niwi\u0144ska A, Sarnowska E et al (2020) Effects of BRCA germline mutations on triple-negative breast cancer prognosis. J Oncol 2020:8545643. https:\/\/doi.org\/10.1155\/2020\/8545643","journal-title":"J Oncol"},{"key":"6692_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10549-015-3293-7","volume":"150","author":"MW Wong-Brown","year":"2015","unstructured":"Wong-Brown MW, Meldrum CJ, Carpenter JE et al (2015) Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat 150:71\u201380. https:\/\/doi.org\/10.1007\/s10549-015-3293-7","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"6692_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17816\/ecogen16362-71","volume":"16","author":"L Gordeeva","year":"2018","unstructured":"Gordeeva L, Lojko I, Voronina E et al (2018) Mutations in tumor suppressor genes and their relationship with phenotypic features of breast cancer in young age women. Ecolo genet 16(3):62\u201371. https:\/\/doi.org\/10.17816\/ecogen16362-71","journal-title":"Ecolo genet"},{"key":"6692_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2478\/jbcr-2018-0017","volume":"11","author":"KS Kovacheva","year":"2018","unstructured":"Kovacheva KS, Kamburova ZB, Popovska SL et al (2018) Prevalence of Five BRCA1\/2 Mutations in Bulgarian Breast Cancer Patients. J Biomed Clin Res 11:123\u2013127. https:\/\/doi.org\/10.2478\/jbcr-2018-0017","journal-title":"J Biomed Clin Res"},{"key":"6692_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-018-5015-4","volume":"173","author":"JM Ryu","year":"2019","unstructured":"Ryu JM, Choi HJ, Kim I et al (2019) Prevalence and oncologic outcomes of BRCA 1\/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Res Treat 173:385\u2013395. https:\/\/doi.org\/10.1007\/s10549-018-5015-4","journal-title":"Breast Cancer Res Treat"},{"key":"6692_CR35","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ijc.23518","volume":"123","author":"F Bertucci","year":"2008","unstructured":"Bertucci F, Finetti P, Cervera N et al (2008) How basal are triple-negative breast cancers? Int J Cancer 123:236\u2013240. https:\/\/doi.org\/10.1002\/ijc.23518","journal-title":"Int J Cancer"},{"key":"6692_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10495-016-1214-9","volume":"21","author":"L Zhang","year":"2016","unstructured":"Zhang L, Yang A, Wang M et al (2016) Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells. Apoptosis 21:473\u2013488. https:\/\/doi.org\/10.1007\/s10495-016-1214-9","journal-title":"Apoptosis"},{"key":"6692_CR37","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.canep.2012.02.001","volume":"36","author":"R Bosviel","year":"2012","unstructured":"Bosviel R, Garcia S, Lavediaux G et al (2012) BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. Cancer Epidemiol 36:e177-182. https:\/\/doi.org\/10.1016\/j.canep.2012.02.001","journal-title":"Cancer Epidemiol"},{"key":"6692_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13058-017-0856-z","volume":"19","author":"S Vos","year":"2017","unstructured":"Vos S, Moelans CB, van Diest PJ (2017) BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers. Breast Cancer Res 19:64. https:\/\/doi.org\/10.1186\/s13058-017-0856-z","journal-title":"Breast Cancer Res"},{"issue":"1","key":"6692_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.32471\/exp-oncology.2312-8852","volume":"43","author":"OE Lobanova","year":"2021","unstructured":"Lobanova OE, Rossokha ZI, Medvedieva NL et al (2021) Prevalence of BRCA1 and BRCA2 genes promoter hypermethylation in breast cancer tissue. Exp Oncol 43(1):56\u201360. https:\/\/doi.org\/10.32471\/exp-oncology.2312-8852","journal-title":"Exp Oncol"},{"key":"6692_CR40","doi-asserted-by":"publisher","first-page":"E910","DOI":"10.3390\/cancers12040910","volume":"12","author":"S Tabano","year":"2020","unstructured":"Tabano S, Azzollini J, Pesenti C et al (2020) Analysis of BRCA1 and RAD51C promoter methylation in italian families at high-risk of breast and ovarian cancer. Cancers (Basel) 12:E910. https:\/\/doi.org\/10.3390\/cancers12040910","journal-title":"Cancers (Basel)"},{"key":"6692_CR41","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3389\/fphar.2018.00909","volume":"9","author":"H Chen","year":"2018","unstructured":"Chen H, Wu J, Zhang Z et al (2018) Association between BRCA status and triple-negative breast cancer: a meta-analysis. Front Pharmacol 9:909. https:\/\/doi.org\/10.3389\/fphar.2018.00909","journal-title":"Front Pharmacol"},{"key":"6692_CR42","doi-asserted-by":"publisher","DOI":"10.3233\/BD-2010-0306.10.3233\/BD-2010-0306","author":"BN Peshkin","year":"2010","unstructured":"Peshkin BN, Alabek ML, Isaacs C (2010) BRCA1\/2 mutations and triple negative breast cancERS. Breast Dis. https:\/\/doi.org\/10.3233\/BD-2010-0306.10.3233\/BD-2010-0306","journal-title":"Breast Dis"},{"key":"6692_CR43","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.3892\/ol.2018.9770","volume":"17","author":"J Huszno","year":"2019","unstructured":"Huszno J, Ko\u0142osza Z, Grzybowska E (2019) BRCA1 mutation in breast cancer patients: analysis of prognostic factors and survival. Oncol Lett 17:1986\u20131995. https:\/\/doi.org\/10.3892\/ol.2018.9770","journal-title":"Oncol Lett"},{"key":"6692_CR44","doi-asserted-by":"publisher","first-page":"175883592097532","DOI":"10.1177\/1758835920975326","volume":"12","author":"L Incorvaia","year":"2020","unstructured":"Incorvaia L, Fanale D, Bono M et al (2020) BRCA1\/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype\u2013phenotype correlation in a cohort of 531 patients. Ther Adv Med Oncol 12:1758835920975326. https:\/\/doi.org\/10.1177\/1758835920975326","journal-title":"Ther Adv Med Oncol"},{"key":"6692_CR45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, Fulton RS, McLellan MD et al (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61\u201370. https:\/\/doi.org\/10.1038\/nature11412","journal-title":"Nature"},{"key":"6692_CR46","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3892\/mco.2021.2258","volume":"14","author":"F Fujisawa","year":"2021","unstructured":"Fujisawa F, Tamaki Y, Inoue T et al (2021) Prevalence of BRCA1 and BRCA2 mutations in Japanese patients with triple-negative breast cancer: a single institute retrospective study. Mol Clin Oncol 14:96. https:\/\/doi.org\/10.3892\/mco.2021.2258","journal-title":"Mol Clin Oncol"},{"key":"6692_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10549-012-2348-2","volume":"137","author":"S Rummel","year":"2013","unstructured":"Rummel S, Varner E, Shriver CD, Ellsworth RE (2013) Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. Breast Cancer Res Treat 137:119\u2013125. https:\/\/doi.org\/10.1007\/s10549-012-2348-2","journal-title":"Breast Cancer Res Treat"},{"key":"6692_CR48","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10549-016-3792-1","volume":"156","author":"M Gonz\u00e1lez-Rivera","year":"2016","unstructured":"Gonz\u00e1lez-Rivera M, Lobo M, L\u00f3pez-Tarruella S et al (2016) Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Breast Cancer Res Treat 156:507\u2013515. https:\/\/doi.org\/10.1007\/s10549-016-3792-1","journal-title":"Breast Cancer Res Treat"},{"key":"6692_CR49","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3892\/ol.2014.1834","volume":"7","author":"G Palomba","year":"2014","unstructured":"Palomba G, Budroni M, Olmeo N et al (2014) Triple-negative breast cancer frequency and type of BRCA mutation: clues from Sardinia. Oncol Lett 7:948\u2013952. https:\/\/doi.org\/10.3892\/ol.2014.1834","journal-title":"Oncol Lett"},{"key":"6692_CR50","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ijc.30771","volume":"141","author":"SL Hamameh","year":"2017","unstructured":"Hamameh SL, Renbaum P, Kamal L et al (2017) Genomic analysis of inherited breast cancer among palestinian women: Genetic heterogeneity and a founder mutation in TP53. Int J Cancer 141:750\u2013756. https:\/\/doi.org\/10.1002\/ijc.30771","journal-title":"Int J Cancer"},{"key":"6692_CR51","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.3747\/co.25.3954","volume":"25","author":"JM Lebert","year":"2018","unstructured":"Lebert JM, Lester R, Powell E et al (2018) Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol 25:S142\u2013S150. https:\/\/doi.org\/10.3747\/co.25.3954","journal-title":"Curr Oncol"},{"key":"6692_CR52","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-011-1711-z","volume":"130","author":"S Bayraktar","year":"2011","unstructured":"Bayraktar S, Gutierrez-Barrera AM, Liu D et al (2011) Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130:145\u2013153. https:\/\/doi.org\/10.1007\/s10549-011-1711-z","journal-title":"Breast Cancer Res Treat"},{"key":"6692_CR53","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11864-019-0682-x","volume":"20","author":"TG Lyons","year":"2019","unstructured":"Lyons TG (2019) Targeted therapies for triple-negative breast cancer. Curr Treat Options Oncol 20:82. https:\/\/doi.org\/10.1007\/s11864-019-0682-x","journal-title":"Curr Treat Options Oncol"},{"key":"6692_CR54","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson ME, Tung N, Conte P et al (2019) OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 30:558\u2013566. https:\/\/doi.org\/10.1093\/annonc\/mdz012","journal-title":"Ann Oncol"},{"key":"6692_CR55","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA et al (2020) Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 31:1526\u20131535. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2098","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06692-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06692-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06692-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T16:03:51Z","timestamp":1662912231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06692-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["6692"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06692-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"18 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and approved by the local ethics committee (Committee on Bioethics: Bogomolets National Medical University, Kyiv (# 0120U100871).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}